Research at Pardes Biosciences Inc. has led to the identification of cysteine protease inhibitors, particularly 3C-like proteinase (3CLpro, Mpro, nsp5; SARS-CoV-2) and Mpro (HCoV-229E virus) inhibitors, reported to be useful for the treatment of viral infections.
Veru Inc. announced results from an in vitro study evaluating the effects of sabizabulin against a prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells.
Researchers from Shandong Academy of Agricultural Science reported the discovery of novel pleuromutilin derivatives as potential antibiotic agents. Synthesis and optimization of a series of pyridinium cation-substituted pleuromutilin analogues led to the identification of compound [I] as the lead candidate with potent antibacterial activity.
On Vaccine Day, Moderna Inc. had to tell the world there weren’t enough flu cases to get a good reading in one of its two phase III vaccine studies. The northern hemisphere clinical trial of mRNA-1010, a seasonal quadrivalent vaccine, did not meet the statistical threshold because there were not enough sick participants to test to determine an interim efficacy analysis.
A recent F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes compounds reported to be useful for the treatment of Escherichia coli infection.
Although COVID-19 may be more severe in people with HIV (PWH), the underlying biological mechanisms among PWH treated with antiretroviral therapy (ART) remain largely unknown.
A live-attenuated vaccine targeting SARS-CoV-2 infection, which can be administered through the nose, has shown promise in preclinical animal studies carried out by researchers in Berlin. In an article published April 3, 2023, in Nature Microbiology, the authors reported that the COVID-19 vaccine candidate – sCPD9 – triggered the most robust immune response in a hamster model when compared with Biontech/Pfizer’s mRNA vaccine BNT162b2 and Ad2-Spike.
RSS
